Alpha-1 MP
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
Conditions
Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
Trial Timeline
Jul 1, 2016 → Feb 1, 2029
NCT ID
NCT02796937About Alpha-1 MP
Alpha-1 MP is a phase 3 stage product being developed by Grifols for Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02796937. Target conditions include Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02870348 | Phase 1/2 | Completed |
| NCT02870309 | Phase 1/2 | Completed |
| NCT02796937 | Phase 3 | Recruiting |
| NCT01983241 | Phase 3 | Active |
Competing Products
20 competing products in Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency